FDA Keeps Tabs on Device Safety After Sales
Published Date: 12/23/2025
Notice
Summary
The FDA is asking for approval to keep collecting info from medical device makers about how their products perform after they hit the market. This helps keep devices safe and effective for everyone. If you’re a manufacturer, get ready to submit reports and plans by January 21, 2026, with no new fees involved.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Manufacturers Face Multi‑Thousand Hour Reporting Burden
If you are a medical device manufacturer required to do postmarket surveillance under 21 CFR part 822, the FDA estimates an annual reporting burden of 4,968 hours for submissions and reports. The largest item is periodic reports (Sec. 822.38) estimated at 4,200 hours from 35 respondents (3 responses each, 40 hours per response); FDA also reports an increase of 1,890 burden hours and 45 annual responses based on internal tracking.
No Capital or Operating Costs Required
The FDA states there are no capital costs or operating and maintenance costs associated with this information collection (OMB Control Number 0910-0449). You will not face new capital or O&M fees tied to this paperwork collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-23631 — Submission for OMB Review; Comment Request
The Department of Agriculture is asking for public feedback on how it collects info about lottery and gambling winnings for SNAP benefits. If you or your household get big lottery or gambling money, you must report it to keep getting food help. Comments are open until January 21, 2026, so now’s the time to speak up and help make the process easier and clearer!
Next: 2025-23632 — Privacy Act of 1974; Matching Program
The Department of Education and the IRS are teaming up again to share info that helps decide who qualifies for student loan repayment plans and federal financial aid like Pell Grants. This matching program kicks off around January 30, 2026, and runs for 18 months, with a chance to extend. It’s all about making sure aid and repayments are fair and accurate, with no extra cost to you!